Streetbeat News

TELO

Telomir Pharmaceuticals Inc

Industry

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Open

4.85

Mkt cap

150M

Volume

70K

High

5.08

P/E Ratio

-6.45

52-wk high

20.72

Low

4.67

Div yield

N/A

52-wk low

3.11

Telomir Pharmaceuticals has announced promising results from its copper binding studies with Telomir-1, which could be used to treat Wilson's disease and other copper-related disorders.

Portfolio Pulse from

December 23, 2024 | 12:45 pm

Telomir Pharmaceuticals announced preclinical results showing that their compound, Telomir-1, can reverse aging and increase longevity in model organisms. This breakthrough positions Telomir as a leader in age-reversal science.

Portfolio Pulse from

November 21, 2024 | 12:15 pm

Nikola Corporation's shares fell by 10.4% after announcing a securities purchase agreement and a mixed shelf offering. Other stocks like Alzamend Neuro and Virax Biolabs saw significant gains, while Liquidia Corporation and Theriva Biologics experienced notable declines.

Portfolio Pulse from Avi Kapoor

August 19, 2024 | 5:37 pm

Telomir Pharmaceuticals announced the passing of its Chairman and CEO, Christopher Chapman, Jr., M.D. Erez Aminov, currently CEO of MIRA Pharmaceuticals, has been appointed as the new CEO and Chairman of Telomir. The company also announced changes to its Board of Directors.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 12:40 pm

Telomir Pharmaceuticals (NASDAQ:TELO) has been added to the Russell 3000 and Russell Microcap Indexes, effective July 1, as part of the 2024 Russell indexes reconstitution.

Portfolio Pulse from Benzinga Newsdesk

July 02, 2024 | 12:34 pm

Telomir Pharmaceuticals has commenced a study to evaluate the safety of Telomir-1 when administered orally to geriatric Beagle dogs for 63 consecutive days. The study began on May 28th, and initial dosing was well-tolerated by all animals. The data will explore the potential for treating age-related conditions.

Portfolio Pulse from Benzinga Newsdesk

May 30, 2024 | 12:37 pm

In Tuesday's after-market session, several healthcare stocks showed significant movement. Predictive Oncology led the gainers with a 36.4% increase, while Concord Medical Services experienced the largest drop, declining by 23.3%. Notably, TransMedics Group and CVRx reported their Q1 earnings, influencing their stock movements.

Portfolio Pulse from Benzinga Insights

April 30, 2024 | 8:31 pm

In Monday's intraday session, several healthcare stocks experienced significant movements. NKGen Biotech led the gainers with a 33.8% increase, while Vaxxinity saw the largest decline among the losers, dropping 52.9%. Other notable movers included MSP Recovery, Assure Holdings, ProKidney, iSpecimen, GlucoTrack, Hepion Pharmaceuticals, Bio-Path Holdings, Inhibikase Therapeutics, Telomir Pharmaceuticals, and Ocean Biomedical. Market capitalizations varied widely among these companies, reflecting diverse investor reactions to recent earnings reports and market dynamics.

Portfolio Pulse from Benzinga Insights

April 22, 2024 | 4:31 pm

Telomir Pharmaceuticals announced pre-clinical data for its age-reversal drug, Telomir-1, showing a 40% increase in telomerase activity and lengthened telomeres in human cells. The company provided endpoints for assessing the drug's effects in dogs and outlined plans for human and animal IND trials targeting osteoarthritis.

Portfolio Pulse from Benzinga Newsdesk

April 16, 2024 | 12:39 pm

In Wednesday's intraday session, several healthcare stocks experienced significant movements. Adial Pharmaceuticals led the gainers with a 61.6% increase, while Acorda Therapeutics headed the losers with a 20.4% decrease. Other notable movers included Jaguar Health, Orgenesis, BioSig Technologies, and Telomir Pharmaceuticals on the gainers' side, and Kineta, DocGo, Biophytis, Yield10 Bioscience, and Eyenovia among the losers.

Portfolio Pulse from Benzinga Insights

April 10, 2024 | 4:31 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.